Bolstering  	Bolstering  	 NNP	B-NP
Components  	Components  	 NNP	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
Immune  	Immune  	 NNP	I-NP
Response  	Response  	 NNP	I-NP
Compromised  	Compromised  	 NNP	O
by  	by  	 IN	O
Prior  	Prior  	 NNP	O
Exposure  	Exposure  	 NNP	O
to  	to  	 TO	O
Adenovirus 	Adenovirus 	 NNP	B-NP
:  	:  	 :	O
Guided  	Guided  	 NNP	B-NP
Formulation  	Formulation  	 NNP	I-NP
Development  	Development  	 NNP	I-NP
for  	for  	 IN	I-NP
a  	a  	 DT	I-NP
Nasal  	Nasal  	 NNP	I-NP
Ebola  	Ebola  	 NNP	I-NP
Vaccine  	Vaccine  	 NNP	I-NP
The  	The  	 DT	O
severity  	severity  	 NN	O
and  	and  	 CC	O
longevity  	longevity  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
Ebola  	Ebola  	 JJ	B-NP
outbreak  	outbreak  	 NN	I-NP
highlight  	highlight  	 VB	O
the  	the  	 DT	O
need  	need  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
fast-acting  	fast-acting  	 JJ	B-NP
yet  	yet  	 RB	O
long-lasting  	long-lasting  	 JJ	O
vaccine  	vaccine  	 NN	O
for  	for  	 IN	O
at-risk  	at-risk  	 JJ	B-NP
populations  	populations  	 NNS	I-NP
( 	( 	 -LRB-	O
medical  	medical  	 JJ	B-NP
personnel  	personnel  	 NNS	I-NP
and  	and  	 CC	O
rural  	rural  	 JJ	B-NP
villagers 	villagers 	 NNS	I-NP
)  	)  	 -RRB-	O
where  	where  	 WRB	O
repeated  	repeated  	 VBN	B-NP
prime-boost  	prime-boost  	 JJ	I-NP
regimens  	regimens  	 NNS	I-NP
are  	are  	 VBP	O
not  	not  	 RB	O
feasible 	feasible 	 JJ	O
.  	.  	 .	O
While  	While  	 IN	O
recombinant  	recombinant  	 JJ	B-NP
adenovirus  	adenovirus  	 NNS	I-NP
( 	( 	 -LRB-	O
rAd 	rAd 	 NNP	B-NP
) 	) 	 -RRB-	O
-based  	-based  	 JJ	O
vaccines  	vaccines  	 NNS	O
have  	have  	 VBP	O
conferred  	conferred  	 JJ	O
full  	full  	 JJ	O
protection  	protection  	 NN	O
against  	against  	 IN	O
multiple  	multiple  	 JJ	O
strains  	strains  	 NNS	O
of  	of  	 IN	O
Ebola  	Ebola  	 NNP	B-NP
after  	after  	 IN	O
a  	a  	 DT	O
single  	single  	 JJ	O
immunization 	immunization 	 NN	B-NP
,  	,  	 ,	O
their  	their  	 PRP$	O
efficacy  	efficacy  	 NN	O
is  	is  	 VBZ	O
impaired  	impaired  	 VBN	O
by  	by  	 IN	O
pre-existing  	pre-existing  	 JJ	B-NP
immunity  	immunity  	 NN	I-NP
( 	( 	 -LRB-	O
PEI 	PEI 	 NNP	B-NP
)  	)  	 -RRB-	O
to  	to  	 TO	O
adenovirus 	adenovirus 	 VB	O
.  	.  	 .	O
To  	To  	 TO	O
address  	address  	 VB	O
this  	this  	 DT	O
important  	important  	 JJ	O
issue 	issue 	 NN	O
,  	,  	 ,	O
a  	a  	 DT	O
panel  	panel  	 NN	O
of  	of  	 IN	O
formulations  	formulations  	 NNS	B-NP
was  	was  	 VBD	O
evaluated  	evaluated  	 VBN	O
by  	by  	 IN	O
an  	an  	 DT	O
in  	in  	 IN	O
vitro  	vitro  	 JJ	B-NP
assay  	assay  	 NN	I-NP
for  	for  	 IN	O
their  	their  	 PRP$	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
protect  	protect  	 VB	O
rAd  	rAd  	 JJ	B-NP
from  	from  	 IN	O
neutralization 	neutralization 	 NN	B-NP
.  	.  	 .	O
An  	An  	 DT	O
amphiphilic  	amphiphilic  	 JJ	B-NP
polymer  	polymer  	 NNS	I-NP
( 	( 	 -LRB-	O
F16 	F16 	 NNP	B-NP
,  	,  	 ,	O
FW  	FW  	 NNP	B-NP
∼39,000 	∼39,000 	 NNP	O
)  	)  	 -RRB-	O
significantly  	significantly  	 RB	O
improved  	improved  	 VBN	O
transgene  	transgene  	 JJ	B-NP
expression  	expression  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
presence  	presence  	 NN	O
of  	of  	 IN	O
anti-Ad  	anti-Ad  	 JJ	B-NP
neutralizing  	neutralizing  	 JJ	O
antibodies  	antibodies  	 NNS	B-NP
( 	( 	 -LRB-	O
NAB 	NAB 	 NNP	B-NP
)  	)  	 -RRB-	O
at  	at  	 IN	O
concentrations  	concentrations  	 NNS	B-NP
of  	of  	 IN	O
5  	5  	 CD	O
times  	times  	 NNS	O
the  	the  	 DT	O
50 	50 	 CD	O
%  	%  	 NN	O
neutralizing  	neutralizing  	 NN	O
dose  	dose  	 NN	O
( 	( 	 -LRB-	O
ND50 	ND50 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
vivo  	vivo  	 JJ	B-NP
performance  	performance  	 NN	I-NP
of  	of  	 IN	I-NP
rAd  	rAd  	 JJ	I-NP
in  	in  	 IN	O
F16  	F16  	 NNP	B-NP
was  	was  	 VBD	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
unformulated  	unformulated  	 JJ	B-NP
virus 	virus 	 NN	I-NP
,  	,  	 ,	O
virus  	virus  	 NN	O
modified  	modified  	 VBN	O
with  	with  	 IN	O
poly 	poly 	 NNS	B-NP
( 	( 	 -LRB-	I-NP
ethylene 	ethylene 	 NN	I-NP
)  	)  	 -RRB-	I-NP
glycol  	glycol  	 NNS	I-NP
( 	( 	 -LRB-	O
PEG 	PEG 	 NNP	B-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
virus  	virus  	 NN	O
incorporated  	incorporated  	 VBN	O
into  	into  	 IN	O
poly 	poly 	 NNS	B-NP
( 	( 	 -LRB-	I-NP
lactic-co-glycolic 	lactic-co-glycolic 	 NNP	I-NP
)  	)  	 -RRB-	I-NP
acid  	acid  	 NN	I-NP
( 	( 	 -LRB-	O
PLGA 	PLGA 	 NNP	B-NP
)  	)  	 -RRB-	O
polymeric  	polymeric  	 JJ	B-NP
beads 	beads 	 NN	I-NP
.  	.  	 .	O
Histochemical  	Histochemical  	 JJ	B-NP
analysis  	analysis  	 NN	I-NP
of  	of  	 IN	O
lung  	lung  	 NN	O
tissue  	tissue  	 NN	O
revealed  	revealed  	 VBD	O
that  	that  	 IN	O
F16  	F16  	 NNP	B-NP
promoted  	promoted  	 VBD	O
strong  	strong  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
transgene  	transgene  	 JJ	B-NP
expression  	expression  	 NN	I-NP
in  	in  	 IN	O
naive  	naive  	 JJ	B-NP
mice  	mice  	 NNS	I-NP
and  	and  	 CC	O
those  	those  	 DT	O
that  	that  	 WDT	O
were  	were  	 VBD	O
exposed  	exposed  	 VBN	O
to  	to  	 TO	O
adenovirus  	adenovirus  	 VB	O
in  	in  	 IN	O
the  	the  	 DT	O
nasal  	nasal  	 JJ	B-NP
cavity  	cavity  	 NN	I-NP
28  	28  	 CD	O
days  	days  	 NNS	O
prior  	prior  	 RB	O
to  	to  	 TO	O
immunization 	immunization 	 VB	B-NP
.  	.  	 .	O
Multiparameter  	Multiparameter  	 JJ	B-NP
flow  	flow  	 NN	I-NP
cytometry  	cytometry  	 VBZ	O
revealed  	revealed  	 VBN	O
that  	that  	 IN	O
F16  	F16  	 CD	B-NP
induced  	induced  	 NNS	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
polyfunctional  	polyfunctional  	 JJ	B-NP
antigen-specific  	antigen-specific  	 JJ	I-NP
CD8+  	CD8+  	 CD	I-NP
T  	T  	 NN	O
cells  	cells  	 NNS	O
simultaneously  	simultaneously  	 RB	O
producing  	producing  	 VBG	B-NP
IFN-γ 	IFN-γ 	 JJ	I-NP
,  	,  	 ,	O
IL-2 	IL-2 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
TNF-α  	TNF-α  	 JJ	B-NP
than  	than  	 IN	O
other  	other  	 JJ	O
test  	test  	 NN	B-NP
formulations 	formulations 	 NNS	I-NP
.  	.  	 .	O
These  	These  	 DT	O
effects  	effects  	 NNS	O
were  	were  	 VBD	O
not  	not  	 RB	O
compromised  	compromised  	 VBN	O
by  	by  	 IN	O
PEI 	PEI 	 NNP	B-NP
.  	.  	 .	O
Data  	Data  	 NNS	O
from  	from  	 IN	O
formulations  	formulations  	 NNS	B-NP
that  	that  	 WDT	O
provided  	provided  	 VBD	O
partial  	partial  	 JJ	O
protection  	protection  	 NN	O
from  	from  	 IN	O
challenge  	challenge  	 NN	O
consistently  	consistently  	 RB	O
identified  	identified  	 VBN	O
specific  	specific  	 JJ	O
immunological  	immunological  	 JJ	B-NP
requirements  	requirements  	 NNS	I-NP
necessary  	necessary  	 JJ	O
for  	for  	 IN	O
protection 	protection 	 NN	O
.  	.  	 .	O
This  	This  	 DT	O
approach  	approach  	 NN	O
may  	may  	 MD	O
be  	be  	 VB	O
useful  	useful  	 JJ	O
for  	for  	 IN	O
development  	development  	 NN	O
of  	of  	 IN	O
formulations  	formulations  	 NNS	B-NP
for  	for  	 IN	O
other  	other  	 JJ	O
vaccine  	vaccine  	 NN	B-NP
platforms  	platforms  	 NNS	I-NP
that  	that  	 WDT	O
also  	also  	 RB	O
employ  	employ  	 VB	O
ubiquitous  	ubiquitous  	 JJ	B-NP
pathogens  	pathogens  	 NN	I-NP
as  	as  	 IN	O
carriers  	carriers  	 NNS	O
like  	like  	 IN	O
the  	the  	 DT	O
influenza  	influenza  	 JJ	B-NP
virus 	virus 	 NN	I-NP
.  	.  	 .	O
